SCHEMBL6326859

SCHEMBL6326859

Cc1ccc(C(Nc2ccc(CN(C)C)cc2)=C2C(=O)Nc3ccccc32)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.41
TP53 P04637 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
IDO1 P14902 2/20 0.40
TDO2 P48775 1/20 0.40
TDP1 Q9NUW8 2/20 0.40
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
LSS P48449 1/20 0.37
TSPO P30536 1/20 0.36
ROCK2 O75116 1/20 0.36
ALDH1A1 P00352 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CSNK1G1 Q9HCP0 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
HPGD P15428 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6326854 1.00 MAPT (0.41) MAPTTP53SMN1; SMN2IDO1TDO2
SCHEMBL6323531 0.92 IDO1 (0.40) MAPTSMN1; SMN2IDO1TDO2TDP1
SCHEMBL30979384 0.92 IDO1 (0.40) MAPTSMN1; SMN2IDO1TDO2TDP1
SCHEMBL6323528 0.92 IDO1 (0.40) MAPTSMN1; SMN2IDO1TDO2TDP1
SCHEMBL6327539 0.91 LSS (0.48) MAPTSMN1; SMN2IDO1TDO2TDP1
SCHEMBL6327035 0.91 LSS (0.48) MAPTSMN1; SMN2IDO1TDO2TDP1
SCHEMBL6322253 0.89 KMT2A (0.40) MAPTTP53SMN1; SMN2IDO1TDO2
SCHEMBL6325570 0.89 TDP1 (0.56) MAPTTP53IDO1TDO2TDP1
SCHEMBL6325573 0.89 TDP1 (0.56) MAPTTP53IDO1TDO2TDP1
SCHEMBL6322247 0.89 KMT2A (0.40) MAPTTP53SMN1; SMN2IDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6855710-B2 Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-02-15 US disclosed
US-20040058978-A1 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-03-25 US disclosed
EP-1115704-B1 NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES BOEHRINGER INGELHEIM PHARMA (DE) 2003-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058978-A1 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs CDK1, CDK2, CDK3 MAPT 3817/4885TP53 915/4885SMN1; SMN2 4425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.